Zevra Therapeutics
ZVRA
2 hedge funds and large institutions have $30K invested in Zevra Therapeutics in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.
1.65% less ownership
Funds ownership: 1.71% → 0.06% (-1.6%)
67% less funds holding
Funds holding: 6 → 2 (-4)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $342K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$193K |
| 2 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$114K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$34K |
| 4 |
Rockefeller Capital Management
New York
|
-$1K |
ZVRA Hedge Fund Activity: Q3 2020 in Review
2 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2020, worth a combined $30K — down 92% from $360K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ZVRA and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Arete Wealth Advisors, exiting entirely with an estimated $193K sold.
- 2 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2020, down from 6 in Q2 2020.
- Funds reported $30K of Zevra Therapeutics stock for Q3 2020, down 92% quarter-over-quarter.
- 0 funds opened new Zevra Therapeutics positions in Q3 2020 and 4 closed out, a net change of -4 holders.
- The largest Zevra Therapeutics seller in Q3 2020 was Arete Wealth Advisors, an estimated $193K sold.
Based on aggregated 13F filings for Q3 2020.